Lyra Therapeutics (LYRA) Change in Accured Expenses (2019 - 2025)
Quarterly Change in Accured Expenses rose 42.96% to -$328000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.8 million through Dec 2025, up 69.69% year-over-year, with the annual reading at -$1.8 million for FY2025, 69.69% up from the prior year.
Lyra Therapeutics' Change in Accured Expenses history spans 7 years, with the latest figure at -$328000.0 for Q4 2025.
- Change in Accured Expenses came in at -$328000.0 for Q4 2025, up from -$942000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q3 2023 to a low of -$3.3 million in Q2 2024.
- The 5-year median for Change in Accured Expenses is -$144500.0 (2022), against an average of -$13950.0.
- Year-over-year, Change in Accured Expenses soared 604.32% in 2022 and then plummeted 2564.37% in 2023.
- Lyra Therapeutics' Change in Accured Expenses stood at $278000.0 in 2021, then skyrocketed by 604.32% to $2.0 million in 2022, then rose by 8.07% to $2.1 million in 2023, then plummeted by 127.17% to -$575000.0 in 2024, then soared by 42.96% to -$328000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Change in Accured Expenses are -$328000.0 (Q4 2025), -$942000.0 (Q3 2025), and -$202000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Lyra Therapeutics | - | - | - | -328,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -328,000.00 |
| Dec 31, 2025 | -328,000.00 |
| Sep 30, 2025 | -942,000.00 |
| Sep 30, 2025 | -942,000.00 |
| Jun 30, 2025 | -202,000.00 |
| Jun 30, 2025 | -202,000.00 |
| Mar 31, 2025 | -339,000.00 |
| Mar 31, 2025 | -339,000.00 |
| Dec 31, 2024 | -575,000.00 |
| Dec 31, 2024 | -575,000.00 |
| Sep 30, 2024 | -2.90 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -3.33 Mn |
| Jun 30, 2024 | -3.33 Mn |
| Mar 31, 2024 | 827,000.00 |
| Mar 31, 2024 | 827,000.00 |
| Dec 31, 2023 | 2.12 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.30 Mn |
| Sep 30, 2023 | 2.30 Mn |
| Jun 30, 2023 | -610,000.00 |
| Jun 30, 2023 | -610,000.00 |
| Mar 31, 2023 | -2.32 Mn |
| Mar 31, 2023 | -2.32 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 1.61 Mn |
| Sep 30, 2022 | 1.61 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | -87,000.00 |
| Mar 31, 2022 | -87,000.00 |
| Dec 31, 2021 | 278,000.00 |
| Dec 31, 2021 | 278,000.00 |
| Sep 30, 2021 | 988,000.00 |
| Sep 30, 2021 | 988,000.00 |
| Jun 30, 2021 | 961,000.00 |
| Jun 30, 2021 | 961,000.00 |
| Mar 31, 2021 | -983,000.00 |
| Mar 31, 2021 | -983,000.00 |
| Dec 31, 2020 | -237,000.00 |
| Dec 31, 2020 | -237,000.00 |
| Sep 30, 2020 | 1.39 Mn |
| Sep 30, 2020 | 1.39 Mn |
| Jun 30, 2020 | -856,000.00 |
| Jun 30, 2020 | -856,000.00 |
| Mar 31, 2020 | -381,000.00 |
| Mar 31, 2020 | -381,000.00 |
| Dec 31, 2019 | 456,000.00 |
| Dec 31, 2019 | 456,000.00 |
| Sep 30, 2019 | 660,000.00 |
| Sep 30, 2019 | 660,000.00 |
| Jun 30, 2019 | 91,000.00 |
| Jun 30, 2019 | 91,000.00 |
| Mar 31, 2019 | 527,000.00 |
| Mar 31, 2019 | 527,000.00 |